Clinical Trials in Pittsburgh

Showing 13561-13580 of 21,047 trials

Understanding Quality and Equity in Wheelchairs for Veterans

NCT01236170

The Department of Veterans Affairs (VA) provides wheelchairs to about 42,000 Veterans with SCI and more than 40,000 Veterans with amputated limbs (AL). Despite VA's efforts to remove financial and other barriers to the provision of wheelchairs to all Veterans who need them, preliminary evidence suggests that disparities exist in the quality of wheelchairs prescribed to racial minorities and low income Veterans with SCI or AL. The proposed project will provide important information to the VA about the quality and equity of wheelchairs provided to Veterans with SCI or AL, and it will identify the patient and provider factors associated with wheelchair provision. Because Veterans with SCI and AL are considered special disability populations, identifying and understanding these factors is a critical first step to developing interventions to increase the quality and equity of wheelchairs provided to all disabled Veterans.

Spinal Cord InjuriesAmputees

VA Office of Research and Development497 participantsStarted Mar 2011

Tampa, Florida, United States • The Bronx, New York, United States • Cleveland, Ohio, United States +2 more locations

COMPLETEDPhase 2< 1 mile

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

NCT00802464

The goal of this randomized observer-blind trial is to further refine the formulation of vaccines containing GSK1437173A in older adults by comparing the cellular and humoral immune responses and the safety profiles of the different formulations.

Herpes Zoster

GlaxoSmithKline410 participantsStarted Jan 2009

Phoenix, Arizona, United States • Pembroke Pines, Florida, United States • Las Vegas, Nevada, United States +9 more locations

Understanding Quality and Equity in Wheelchairs for Veterans

Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine With Various Formulations in Adults >= 50 Years

Find Trials by Condition in Pittsburgh

Clinical Study to Evaluate the Therapeutic Equivalence of Ketoconazole Cream 2% in the Treatment of Tinea Pedis

A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Multi Center Site , Controlled Trial Comparing a Bioengineered Skin Substitute to a Human Skin Allograft

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

RNS® System LTT Study

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

Non-healing Diabetic Foot Ulcers (DFU) Treated With SoC With or Without NEOX®CORD 1K

Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)

Peanut Epicutaneous Phase II Immunotherapy Clinical Trial

A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas

Irradiation of Large Lung Tumors or Two or More Lung Metastases Simultaneously

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

Healthy Weight Poster, Multi-site Study

Dose Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2849330 in Subjects With Advanced Her3-Positive Solid Tumors

Profound Dermal and SubQ Cartridges for the Treatment of Cellulite

A Multi-Center Study in Men With Acquired Hypogonadotropic Hypogonadism to Compare Changes in Body Composition and Metabolic Parameters With Diet and Exercise in Conjunction With Treatment With 12.5 mg or 25 mg Enclomiphene

Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas